Projects

Mgr. Verona Buociková, PhD.

International

Current
  • Reversing Epitranscriptomic Alterations for CHemosensitization of Pancreatic Cancer
    Program: ERANET
    Duration: 1. 9. 2024 – 31. 8. 2027
Finished
  • Resistance under treatment in breast cancer
    Program: ERANET
    Duration: 1. 8. 2020 – 31. 5. 2024
  • A4L_ACTIONS Efficacy of 5-fluorocytosine metabolic conversion by extracellular vesicle-mediated gene therapy
    Program: Other
    Duration: 1. 11. 2022 – 31. 10. 2023
  • Establishing an algorithm for the early diagnosis and follow-up of patients with pancreatic neuroendocrine tumors
    Program: ERANET
    Duration: 1. 9. 2019 – 31. 3. 2023

National

Current
  • Targeting high-order chromatin regulation for the treatment of poor prognosis uveal melanoma
    Program: SRDA
    Duration: 1. 7. 2024 – 30. 6. 2028
  • Innovative approaches to the diagnosis and treatment of pancreatic ductal adenocarcinoma
    Program:
    Duration: 1. 9. 2024 – 30. 6. 2026
  • Reprogramming pancreatic ductal adenocarcinoma microenvironment towards immunotherapy
    Program: SRDA
    Duration: 1. 7. 2022 – 30. 6. 2026
  • Recreating Pancreatic Ductal Adenocarcinoma Complexity: Implementation of Organ-on-a-Chip Technology for Enhanced Therapeutic Insights
    Program: PostdokGrant
    Duration: 1. 7. 2024 – 31. 12. 2025
Finished
  • Suicide gene therapy mediated by mesenchymal stromal and pancreatic tumor cell-excreted extracellular vesicles in the treatment of pancreatic ductal adenocarcinoma
    Program: SRDA
    Duration: 1. 7. 2021 – 30. 6. 2025
  • Identification of potential therapeutic targets associated with cisplatin resistance in yolk sac tumors
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • The role of mitochondria in progression of colorectal cancer
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • Development of patients derived xenografts models and their utilization for personalized treatment of uveal melanoma
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • Unraveling the role of genetic predispositions in the context of breast cancer tumor microenvironment
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2023
  • Identification of chemoresistant cell populations with metastatic potential in colorectal carcinoma
    Program: VEGA
    Duration: 1. 1. 2019 – 31. 12. 2022
  • TArgetiNg Dna mEthylation by epigenetic editing and its implementation into personalised diagnostics and therapy of uveal Melanoma
    Program: SRDA
    Duration: 1. 8. 2018 – 31. 12. 2022
  • The dynamics of inflammation-induced epigenetic changes during epithelial-to-mesenchymal transition and their role in human pancreatic ductal adenocarcinoma progression
    Program: VEGA
    Duration: 1. 1. 2018 – 31. 12. 2021
  • Turning cisplatin-resistant testiular germ cell tumors into a curable disease
    Program: SRDA
    Duration: 1. 8. 2018 – 31. 12. 2021
  • DNA methylation profiles in genes associated with breast cancer metasasising
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2018
Employees